{
  "drugid": "RxNorm:6472",
  "drugname": "lovastatin",
  "guidelinename": "SLCO1B1, ABCG2, CYP2C9, and Statins",
  "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
  "guidelinepharmgkbids": [
    "PA166105005",
    "PA166262221",
    "PA166262241",
    "PA166262261",
    "PA166262281",
    "PA166262321",
    "PA166262341"
  ],
  "citations": [
    {
      "pmid": "22617227",
      "title": "The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy",
      "authors": [
        "Wilke R A",
        "Ramsey L B",
        "Johnson S G",
        "Maxwell W D",
        "McLeod H L",
        "Voora D",
        "Krauss R M",
        "Roden D M",
        "Feng Q",
        "Cooper-Dehoff R M",
        "Gong L",
        "Klein T E",
        "Wadelius M",
        "Niemi M"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2012
    },
    {
      "pmid": "24918167",
      "title": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update",
      "authors": [
        "Ramsey Laura B",
        "Johnson Samuel G",
        "Caudle Kelly E",
        "Haidar Cyrine E",
        "Voora Deepak",
        "Wilke Russell A",
        "Maxwell Whitney D",
        "McLeod Howard L",
        "Krauss Ronald M",
        "Roden Dan M",
        "Feng Qiping",
        "Cooper-DeHoff Rhonda M",
        "Gong Li",
        "Klein Teri E",
        "Wadelius Mia",
        "Niemi Mikko"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2014
    },
    {
      "pmid": "35152405",
      "title": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.",
      "authors": [
        "Cooper-DeHoff Rhonda M",
        "Niemi Mikko",
        "Ramsey Laura B",
        "Luzum Jasmine A",
        "Tarkiainen E Katriina",
        "Straka Robert J",
        "Gong Li",
        "Tuteja Sony",
        "Wilke Russell A",
        "Wadelius Mia",
        "Larson Eric A",
        "Roden Dan M",
        "Klein Teri E",
        "Yee Sook Wah",
        "Krauss Ronald M",
        "Turner Richard M",
        "Palaniappan Latha",
        "Gaedigk Andrea",
        "Giacomini Kathleen M",
        "Caudle Kelly E",
        "Voora Deepak"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022
    }
  ],
  "recommendations": [
    {
      "implications": {
        "SLCO1B1": "Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk"
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.",
      "classification": "Moderate",
      "phenotypes": {
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "population general",
      "genotypes": null
    },
    {
      "implications": {
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses based on disease-specific guidelines.",
      "classification": "Strong",
      "phenotypes": {
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "population general",
      "genotypes": null
    },
    {
      "implications": {
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "SLCO1B1": "Indeterminate"
      },
      "comments": "n/a",
      "population": "population general",
      "genotypes": null
    },
    {
      "implications": {
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses based on disease-specific guidelines.",
      "classification": "Strong",
      "phenotypes": {
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "population general",
      "genotypes": null
    },
    {
      "implications": {
        "SLCO1B1": "Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk"
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).",
      "classification": "Moderate",
      "phenotypes": {
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "population general",
      "genotypes": null
    },
    {
      "implications": {
        "SLCO1B1": "Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk"
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.",
      "classification": "Moderate",
      "phenotypes": {
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "population general",
      "genotypes": null
    }
  ],
  "genes": [
    "SLCO1B1"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.21.0",
  "source": "CPIC"
}